Literature DB >> 31925480

[Sonographic diagnostics of liver tumors].

C Höner Zu Siederdissen1, A Potthoff2.   

Abstract

Liver tumors are often incidentally found during ultrasound examinations. The decision on further diagnostic imaging depends on the clinical context and the appearance in B mode ultrasound. This review highlights the role of grey scale and contrast-enhanced ultrasound (CEUS) and summarizes the ultrasonographic key features of the most common benign and malignant liver tumors. Conventional grey scale ultrasound is recommended in several guidelines for screening and follow-up of liver tumors in certain risk populations but its ability to characterize liver tumors is limited in most cases. The CEUS has an excellent tolerability and enables liver tumor characterization with a high sensitivity and specificity. The diagnostic value of CEUS is comparable to magnetic resonance imaging. In the case of unclear lesions, inconclusive findings by different imaging methods or if molecular targeted treatment is pursued, ultrasound-guided biopsy is often mandatory. Ultrasound is a rapidly and ubiquitously available method for the detection of liver tumors and CEUS is the only imaging method that enables real-time examination of all contrast phases in the liver. It should therefore be used as the first line imaging method for liver tumor characterization.

Entities:  

Keywords:  Contrast-enhanced ultrasound; Focal nodular hyperplasia; Hemangioma; Hepatocellular adenoma; Hepatocellular carcinoma

Mesh:

Substances:

Year:  2020        PMID: 31925480     DOI: 10.1007/s00108-019-00728-5

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  30 in total

1.  Frequency of tumor entities among liver tumors of unclear etiology initially detected by sonography in the noncirrhotic or cirrhotic livers of 1349 patients. Results of the DEGUM multicenter study.

Authors:  K Seitz; C Greis; A Schuler; T Bernatik; W Blank; C F Dietrich; D Strobel
Journal:  Ultraschall Med       Date:  2011-12-09       Impact factor: 6.548

2.  [EFSUMB-guidelines for CEUS are directive and effective].

Authors:  K Seitz
Journal:  Ultraschall Med       Date:  2010-06-01       Impact factor: 6.548

3.  Assessment of arterial hypervascularity of hepatocellular carcinoma: comparison of contrast-enhanced US and gadoxetate disodium-enhanced MR imaging.

Authors:  Katsutoshi Sugimoto; Fuminori Moriyasu; Junji Shiraishi; Kazuhiro Saito; Junichi Taira; Toru Saguchi; Yasuharu Imai
Journal:  Eur Radiol       Date:  2012-01-24       Impact factor: 5.315

4.  Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival.

Authors:  Valentina Santi; Franco Trevisani; Annagiulia Gramenzi; Alice Grignaschi; Federica Mirici-Cappa; Paolo Del Poggio; Maria Anna Di Nolfo; Luisa Benvegnù; Fabio Farinati; Marco Zoli; Edoardo Giovanni Giannini; Franco Borzio; Eugenio Caturelli; Maria Chiaramonte; Mauro Bernardi
Journal:  J Hepatol       Date:  2010-04-27       Impact factor: 25.083

5.  Gray scale and contrast-enhanced ultrasound imaging of malignant liver tumors of vascular origin.

Authors:  Nora Schweitzer; Bisharah Soudah; Michael Gebel; Michael Peter Manns; Bita Boozari
Journal:  United European Gastroenterol J       Date:  2015-02       Impact factor: 4.623

6.  Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound.

Authors:  Maria Assunta Zocco; Matteo Garcovich; Andrea Lupascu; Enrico Di Stasio; Davide Roccarina; Brigida Elenora Annicchiarico; Laura Riccardi; Maria Elena Ainora; Francesca Ponziani; Gianluigi Caracciolo; Gian Lodovico Rapaccini; Raffaele Landolfi; Massimo Siciliano; Maurizio Pompili; Antonio Gasbarrini
Journal:  J Hepatol       Date:  2013-06-25       Impact factor: 25.083

7.  Tumor-specific vascularization pattern of liver metastasis, hepatocellular carcinoma, hemangioma and focal nodular hyperplasia in the differential diagnosis of 1,349 liver lesions in contrast-enhanced ultrasound (CEUS).

Authors:  D Strobel; K Seitz; W Blank; A Schuler; C F Dietrich; A von Herbay; M Friedrich-Rust; T Bernatik
Journal:  Ultraschall Med       Date:  2009-08-17       Impact factor: 6.548

8.  Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation.

Authors:  Jean-Charles Nault; Gabrielle Couchy; Charles Balabaud; Guillaume Morcrette; Stefano Caruso; Jean-Frederic Blanc; Yannick Bacq; Julien Calderaro; Valérie Paradis; Jeanne Ramos; Jean-Yves Scoazec; Viviane Gnemmi; Nathalie Sturm; Catherine Guettier; Monique Fabre; Eric Savier; Laurence Chiche; Philippe Labrune; Janick Selves; Dominique Wendum; Camilla Pilati; Alexis Laurent; Anne De Muret; Brigitte Le Bail; Sandra Rebouissou; Sandrine Imbeaud; Paulette Bioulac-Sage; Eric Letouzé; Jessica Zucman-Rossi
Journal:  Gastroenterology       Date:  2016-12-07       Impact factor: 22.682

9.  Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience.

Authors:  Paulette Bioulac-Sage; Hervé Laumonier; Gabrielle Couchy; Brigitte Le Bail; Antonio Sa Cunha; Anne Rullier; Christophe Laurent; Jean-Frédéric Blanc; Gaelle Cubel; Hervé Trillaud; Jessica Zucman-Rossi; Charles Balabaud; Jean Saric
Journal:  Hepatology       Date:  2009-08       Impact factor: 17.425

10.  Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis.

Authors:  Amit G Singal; Anjana Pillai; Jasmin Tiro
Journal:  PLoS Med       Date:  2014-04-01       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.